Form 4: Pfizer Director Mortimer Buckley Acquires Phantom Stock

Pfizer Inc. Director Mortimer J. Buckley was granted 7,686.539 phantom stock units as part of deferred director compensation.

Summary

• Director Mortimer J. Buckley acquired 7,686.539 phantom stock units on April 23, 2026.
• The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each phantom unit represents one share of common stock, valued at $26.67 per unit.
• Following this transaction, the director holds a total of 24,391.124 phantom stock units.
• These units are settled in cash or common stock upon the director's retirement from the Board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Demonstrates alignment of director interests with long-term shareholder value through equity-linked compensation.

Negatives

• None identified; this is a standard director compensation disclosure.

Risks

• Value of phantom stock units is subject to the future market performance of Pfizer common stock.

Future Outlook

The units will be settled in cash or common stock upon the director's retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that deferred compensation plans for non-employee directors are standard practice in the pharmaceutical industry to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The use of phantom stock units for director compensation is consistent with governance practices at large-cap pharmaceutical peers such as Merck, Bristol Myers Squibb, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation arrangement.

Next Steps

• No further action required; units will remain held until the director's retirement.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Trading, Director Compensation, Phantom Stock